Investigation of the efficacy of inflawell syrup on covid-19 patients
Phase 2
- Conditions
- COVID-19.Coronavirus infection, unspecifiedB34.2
- Registration Number
- IRCT20170315033086N10
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
COVID-19 patient admitted to the infectious ward of the hospital
Age = 18 years in both sexes
Confirmation of SARS-CoV2 infection based on PCR test and clinical manifestations including: 1. Respiratory distress (breathing = 25 times per minute) or 2. Percentage of oxygen saturation at rest =92%
Early diagnosis (less than or equal to 8 days from the onset of symptoms)
Signing the informed consent form
Exclusion Criteria
Liver, kidney and heart failure
Inability of the patient to consume the oral form
Pregnancy and lactation or positive pregnancy test
Participate in two or more clinical trials simultaneously
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Duration of hospital stay. Timepoint: Day 7 and 14 after the intervention. Method of measurement: Number of days.
- Secondary Outcome Measures
Name Time Method C-reactive protein (CRP). Timepoint: Baseline and 14 days after intervention. Method of measurement: ELISA technique.